Rokit Healthcare Surges on AI Skin Cancer Regeneration Breakthrough
Creatrip Team
a year ago
Rokit Healthcare's shares saw a significant rise after a successful trial in Japan, showcasing their AI skin regeneration platform's ability to regenerate skin tissues in skin cancer patients. This innovation, particularly beneficial for elderly or systemic illness patients, marks a paradigm shift from conventional treatments. The platform's global commercialization is set for later this year. Meanwhile, GL PharmTech's merger with its subsidiary is expected to enhance managerial efficiency. Aptamer Sciences saw stock volatility amid denied acquisition rumors by Aribio.
